Analyst Price Targets — MRK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 25, 2026 12:07 pm | Jasper Hellweg | Argus Research | $170.00 | $153.61 | TheFly | Merck price target raised to $170 from $145 at Argus |
| August 25, 2026 9:52 am | Alexandria Hammond | Wolfe Research | $180.00 | $150.69 | TheFly | Merck price target raised to $180 from $155 at Wolfe Research |
| August 21, 2026 10:25 am | — | Goldman Sachs | $160.00 | $149.25 | TheFly | Merck price target raised to $160 from $140 at Goldman Sachs |
| August 20, 2026 12:47 pm | — | BMO Capital | $170.00 | $149.65 | TheFly | Merck price target raised to $170 from $142 at BMO Capital |
| August 20, 2026 10:44 am | — | UBS | $175.00 | $152.22 | TheFly | Merck price target raised to $175 from $145 at UBS |
| August 20, 2026 9:04 am | — | RBC Capital | $150.00 | $152.22 | TheFly | Merck downgraded to Sector Perform from Outperform at RBC Capital |
| August 20, 2026 6:49 am | Matthew Weston | UBS | $150.00 | $152.22 | StreetInsider | UBS Downgrades Merck (MRK) to Neutral |
| August 19, 2026 8:28 pm | — | Morgan Stanley | $179.00 | $152.22 | TheFly | Merck upgraded to Overweight from Equal Weight at Morgan Stanley |
| August 12, 2026 9:51 am | — | Daiwa | $143.00 | $130.45 | TheFly | Daiwa upgrades Merck to Outperform on pipeline success |
| August 11, 2026 11:12 am | Jasper Hellweg | Argus Research | $145.00 | $130.90 | StreetInsider | Merck (MRK) PT Raised to $145 at Argus |
Latest News for MRK
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference.
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
Johnson and Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.